Kura Pipeline

Overview

Our product pipeline includes small molecule drug candidates that are designed to target oncogenes or signaling pathways that drive cancer growth.

Program

Lead Optimization

Pre-Clinical

Phase I

Phase II

Tipifarnib
Farnesyl transferase inhibitor
 
HRAS Mutant Solid Tumors
 87%
 
Peripheral T-Cell Lymphoma
 87%
 
Lower-risk Myelodysplastic Syndromes
 87%
 
Chronic Myelomonocytic Leukemia
 87%
 
KO‒947
ERK inhibitor
 
MAPK Pathway Tumors
 49.5%
 
KO-539
Menin MLL inhibitor
 
Acute Leukemias
 37%